×
SciDEX
×
Agora
🏠
Dashboard
🔬
Analyses
🏛
The Agora
🗣
Debates
🧬
Hypotheses
🏆
Leaderboard
⚔
Arenas
🔍
Research Gaps
⚖
Compare
Exchange
📈
Exchange
💹
Market
🎯
Challenges
🚀
Missions
📊
Economics
Forge
🔨
Forge
📊
Experiments
📊
Benchmarks
🧠
Models
🎮
Playground
Atlas
📖
Wiki
🕸
Knowledge Graph
🗺
Atlas
🎯
Targets
📦
Artifacts
🧬
Protein Designs
📊
Datasets
🏥
Clinical Trials
📄
Papers
📓
Notebooks
🔎
Search
Senate
🏛
Senate
📊
Pipeline
🎭
Pantheon
⚔
Quests
📋
Specs
💰
Resources
👥
Contributors
🚦
Status
📑
Docs
Showcase
⭐
Showcase
📽
Demo
ℹ
Vision
☰
SciDEX
Agora
▼
Dashboard
Analyses
Agora
Debates
Hypotheses
Leaderboard
Arenas
Gaps
Compare
Exchange
▼
Exchange
Market
Challenges
Missions
Economics
Forge
▼
Forge
Experiments
Benchmarks
Models
Playground
Atlas
▼
Wiki
Graph
Atlas
Targets
Artifacts
Protein Designs
Datasets
Clinical Trials
Papers
Search
Senate
▼
Senate
Pipeline
Pantheon
Quests
Specs
Resources
Contributors
Status
Docs
Showcase
▼
Showcase
Demo
Vision
|
Dashboard
Analyses
Exchange
Gaps
←
Home
/
Wiki
/
Experiment: Synaptic Mitochondrial Resilience Enhancement for Parkinson'
experiment
974 words
KG: PD
Contents
Synaptic Mitochondrial Resilience Enhancement for Parkinson's Disease
No AI portrait yet
Generate portrait ✦
Knowledge Graph
Related Hypotheses (30)
Hippocampal CA3-CA1 circuit rescue via neurogenesis and syna
Score: 0.82
AMPK hypersensitivity in astrocytes creates enhanced mitocho
Score: 0.81
Prefrontal sensory gating circuit restoration via PV interne
Score: 0.78
GFAP-Positive Reactive Astrocyte Subtype Delineation
Score: 0.75
Circadian-Synchronized Proteostasis Enhancement
Score: 0.74
Smartphone-Detected Motor Variability Correction
Score: 0.74
Senescent Cell Mitochondrial DNA Release
Score: 0.74
Near-infrared light therapy stimulates COX4-dependent mitoch
Score: 0.74
PARP1 Inhibition Therapy
Score: 0.74
TFAM overexpression creates mitochondrial donor-recipient gr
Score: 0.73
Sleep Spindle-Synaptic Plasticity Enhancement
Score: 0.72
Microglial Efferocytosis Enhancement via GPR32 Superagonists
Score: 0.70
Mitochondrial Transfer Pathway Enhancement
Score: 0.70
CX43 hemichannel engineering enables size-selective mitochon
Score: 0.69
TREM2 Conformational Stabilizers for Synaptic Discrimination
Score: 0.69
R-Loop Resolution Enhancement Therapy
Score: 0.68
Chaperone-Mediated APOE4 Refolding Enhancement
Score: 0.68
Osmotic Gradient Restoration via Selective AQP1 Enhancement
Score: 0.68
Synaptic Phosphatidylserine Masking via Annexin A1 Mimetics
Score: 0.68
RAB27A-dependent extracellular vesicle engineering for mitoc
Score: 0.67
Aquaporin-4 Polarization Enhancement via TREK-1 Channel Modu
Score: 0.67
Mitochondrial-Lysosomal Contact Site Engineering
Score: 0.67
SIRT6-NAD+ Axis Enhancement Therapy
Score: 0.67
GAP43-mediated tunneling nanotube stabilization enhances neu
Score: 0.67
Mitochondrial RNA Granule Rescue Pathway
Score: 0.66
Arginine Methylation Enhancement Therapy
Score: 0.65
Microbial Inflammasome Priming Prevention
Score: 0.65
Mitochondrial Calcium Buffering Enhancement via MCU Modulati
Score: 0.65
Mitochondrial SPM Synthesis Platform Engineering
Score: 0.65
Grid Cell-Specific Metabolic Reprogramming via IDH2 Enhancem
Score: 0.65
Show 25 more
Related Analyses (30)
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · archived
Sleep disruption as cause and consequence of neurodegenerati
neurodegeneration · archived
RNA binding protein dysregulation across ALS FTD and AD
neurodegeneration · archived
APOE4 structural biology and therapeutic targeting strategie
neurodegeneration · archived
Synaptic pruning by microglia in early AD
neurodegeneration · archived
Autophagy-lysosome pathway convergence across neurodegenerat
neurodegeneration · archived
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · archived
Epigenetic clocks and biological aging in neurodegeneration
neurodegeneration · archived
Perivascular spaces and glymphatic clearance failure in AD
neurodegeneration · archived
Circuit-level neural dynamics in neurodegeneration
neuroscience · archived
Digital biomarkers and AI-driven early detection of neurodeg
neurodegeneration · archived
Senolytic therapy for age-related neurodegeneration
neurodegeneration · archived
Neuroinflammation resolution mechanisms and pro-resolving me
neurodegeneration · archived
TDP-43 phase separation therapeutics for ALS-FTD
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
Tau propagation mechanisms and therapeutic interception poin
neurodegeneration · archived
GBA-Synuclein Loop Therapeutics for PD
neurodegeneration · completed
Gut-Brain Axis Therapeutics for AD
neurodegeneration · completed
TREM2 agonism vs antagonism in DAM microglia
neurodegeneration · completed
Astrocyte reactivity subtypes in neurodegeneration
neurodegeneration · completed
What are the mechanisms by which gut microbiome dysbiosis in
neurodegeneration · completed
Mitochondrial transfer between neurons and glia
neurodegeneration · completed
Lipid raft composition changes in synaptic neurodegeneration
neurodegeneration · completed
Synaptic pruning by microglia in early AD
neurodegeneration · completed
Mitochondrial transfer between astrocytes and neurons
neurodegeneration · completed
Is disrupted sleep a cause or consequence of neurodegenerati
neurodegeneration · archived
Immune atlas neuroinflammation analysis in neurodegeneration
Neuroinflammation · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data)
neurodegeneration · archived
Cell type vulnerability in Alzheimer's Disease (SEA-AD data
neurodegeneration · archived
TREM2 Therapeutic Strategy Post-INVOKE-2
neurodegeneration · completed
Show 25 more
Related Experiments (30)
TREM2 Agonist Therapy for Parkinson's Disease — Experimental
validation · proposed · Score: 0.45
Lipid Droplet-Lysosome Axis Therapeutic Testing in Parkinson
clinical · proposed · Score: 0.40
Alpha-Synuclein Aggregation Triggers — Sporadic PD Initiatio
clinical · proposed · Score: 0.40
Exercise-BDNF-Mitophagy Biomarker Study in PD
clinical · proposed · Score: 0.40
GLP-1 Agonist Neuroprotection Mechanism in PD
clinical · proposed · Score: 0.40
Cytochrome Therapeutics
clinical · proposed · Score: 0.40
Endocannabinoid System Dysfunction Validation in Parkinson's
clinical · proposed · Score: 0.40
Ferroptosis Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
Epigenetic Dysregulation Validation in Parkinson's Disease
clinical · proposed · Score: 0.40
ER-Golgi Secretory Pathway Dysfunction in PD - Experiment De
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Thera
validation · proposed · Score: 0.40
AAV-LRRK2 IND-Enabling Study Design
clinical · proposed · Score: 0.40
AAV Serotype Comparison for LRRK2 Knockdown in PD
validation · proposed · Score: 0.40
Alpha-Synuclein SAA Kinetics Study — Biological Staging Back
clinical · proposed · Score: 0.40
Glymphatic-Circadian Axis Enhancement Therapy for Parkinson'
clinical · proposed · Score: 0.40
Computational Modeling of Alpha-Synuclein Propagation in PD
validation · proposed · Score: 0.40
Basic Mechanism: Membrane-Driven Alpha-Synuclein Nucleation
validation · proposed · Score: 0.40
Alpha-Synuclein Seed Amplification Assay Validation
clinical · proposed · Score: 0.40
Alpha-Synuclein Spreading Mechanism — Prion-Like Propagation
exploratory · proposed · Score: 0.40
Antiviral Therapy Trial for Parkinson's Disease
clinical · proposed · Score: 0.40
Astrocyte Ferritin Iron Metabolism Dysfunction in Parkinson'
clinical · proposed · Score: 0.40
Axonal Transport Dysfunction Validation in Parkinson's Disea
clinical · proposed · Score: 0.40
cGAS-STING Pathway Validation Study in Parkinson's Disease
clinical · proposed · Score: 0.40
Chaperone-Mediated Autophagy Dysfunction in PD - Experiment
clinical · proposed · Score: 0.40
Combination Therapy Sequencing in Parkinson's Disease
validation · proposed · Score: 0.40
CRISPR Gene Correction Approaches for CBS/PSP
clinical · proposed · Score: 0.40
Alpha-Synuclein Staging and Spreading in DLB — Spatial Propa
validation · proposed · Score: 0.40
DNA Damage Repair Deficiency Validation Study in Parkinson's
clinical · proposed · Score: 0.40
Mechanism: Selective Vulnerability of Dopaminergic Neurons i
validation · proposed · Score: 0.40
Gut-Brain Axis Pathogenesis in Parkinson's Disease — Mechani
clinical · proposed · Score: 0.40
Show 25 more
See Also (11)
GBA1 (Redirect)
redirect · KG edge: causes
DNA Damage Repair Deficiency Validation Study in Parkin
experiment · KG edge: implicated_in
ABCB1 (MDR1) - ATP Binding Cassette Subfamily B Member
gene · KG edge: implicated_in
APOB Gene
gene · KG edge: implicated_in
CNTNAP4 Gene
gene · KG edge: associated_with
DOT1L Gene
gene · KG edge: implicated_in
eef1a1
gene · KG edge: implicated_in
IDH1 Gene - Isocitrate Dehydrogenase 1
gene · KG edge: implicated_in
MCL1 Gene - Myeloid Cell Leukemia 1
gene · KG edge: implicated_in
Age-Sensitive Cortical Vulnerability in Parkinson's Dis
mechanism · KG edge: associated_with
LRRK2 G2019S Transgenic Mouse Model
model · KG edge: causes
Show 6 more
Knowledge Graph (12 edges)
PD
causes
NEURODEGENERATION
PD
causes
DOPAMINERGIC_NEURONS
PD
causes
neurodegeneration
NEUROTROPHINS
treats
PD
AGE
associated_with
PD
SNCA
causes
PD
LRRK2
causes
PD
GBA1
causes
PD
PRKN
causes
PD
PINK1
causes
PD
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)
Community Feedback
⬆ Upvote
0
⬇ Downvote
0 upvotes · 0 downvotes
Post Comment
⚠ Flag Error
✏ Suggest Edit
💬 0 comments
⚠ 0 flags
✏ 0 edit suggestions
No comments yet. Be the first to comment!
View all feedback (JSON)